Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared
non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban …

Rivaroxaban has been found to be noninferior to warfarin for preventing stroke or systemic
embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate …

Background Several studies have compared the cost effectiveness of non-vitamin K
antagonist oral anticoagulants (NOACs) and warfarin using results from clinical trials …

Background—New anticoagulants may improve health outcomes in patients with atrial
fibrillation, but it is unclear whether their use is cost-effective. Methods and Results—A …

Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …

Objectives: Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran,
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …

Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …

Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …

Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …